Extraordinary goals call for extraordinary collaborations. By linking our collective insights and capabilities, we can push through the unknown to deliver better pathways to healthcare.



A next-generation manufacturing R&D collaboration, and expense- and revenue-sharing model for successfully commercialized oncology products.


Be Bio

A strategic collaboration to advance rare disease programs using Be Bio’s proprietary engineered B Cell Medicines (BCMs) platform. Be Bio and Resilience are investing in programs to drive innovation and reliability in cell therapy manufacturing, a critical success factor for broad and meaningful patient impact. Be Bio is harnessing the power of the human B cell to create a new class of cellular medicines that durably and redosably produce therapeutic proteins in vivo without toxic pre-conditioning.


BitBio combines the concepts of cell programming and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.

This is possible with our precision human cellular reprogramming technology opti-oxTM – a gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale.

Bridgebio logo


Resilience and BridgeBio have a strategic multi-year partnership focused on advancing future gene therapy treatments, where Resilience will manufacture BridgeBio’s lead investigational gene therapy treatments, BBP-631 and BBP-812. The partnership provides an innovative, capital efficient, sustainable model for BridgeBio to develop, test and deliver transformative medicines for patients more quickly. As part of an innovative risk-sharing framework, BridgeBio will transfer its manufacturing process for its lead AAV-based gene therapy candidates to Resilience’s network of gene therapy sites and Resilience will provide in-kind manufacturing services and will receive future development and approval milestones on BBP-631 and BBP-812.


California Institute of Regenerative Medicine

Resilience has been named a launch Industry Resource Partner by CIRM and is providing access to its GMP biomanufacturing services for CIRM Translational and Clinical Stage projects. In addition to providing access to its cell therapy manufacturing services and partnering opportunities, Resilience will provide project consultation that could aid CIRM applicants in drafting manufacturing plans and budgets for CIRM applications. The two organizations are also developing workplace opportunities in biomanufacturing, including internships to benefit underrepresented groups in the biopharma industry.


Parvus Therapeutics

Parvus is developing a pipeline of novel Navacim™ therapeutic candidates which generate disease-specific Treg cells in vivo to reverse autoimmune disease without impairing normal immune function.


Parker Institute for Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is the largest network of immuno-oncology expertise in the world. With unprecedented collaboration between leading immunotherapy researchers, cancer centers and industry and nonprofit partners, PICI is working to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases.



Pluristyx is dedicated to assisting clients in the development of revolutionary cellular therapeutics. Pluristyx offers a portfolio of induced Pluripotent Stem Cell (iPSC) products that are available in both research and clinical grade, as well as services that are widely applicable to numerous allogenic cellular therapies. Pluristyx also provides end-to-end support for early product development, lowering the barrier to entry, provides a swift translation to clinic, and ensures the best path to commercialization for the next generation of iPSC-derived treatments.



Mayo Clinic

Resilience will collaborate with Mayo Clinic’s Center for Regenerative Medicine to deliver novel biotherapeutics for rare and complex conditions. The focus will be on therapies derived from biologics — cells, blood, enzymes, tissues, genes, or genetically engineered cells — for use in medicines.

Learn more about Mayo Clinic’s Center for Regenerative Medicine here. 


CTMC / A joint venture between Resilience + MD Anderson Cancer Center  

CTMC is a joint venture between Resilience and MD Anderson Cancer Center. CTMC was created to bring together the leading complex biologics manufacturing technology organization and the #1 clinical cancer center to enable innovation from academia and biotech to accelerate cell therapy’s impact for cancer patients. Our 60,000 sq ft facility with development labs and 14 GMP cleanrooms is located in Houston’s Texas Medical Center. Learn more about CTMC here.


MicrosoftTeams-image (3)


Labcorp Cell & Gene Therapy is committed to helping you transform the future of healthcare by bringing promising cell and gene therapies to more patients. Our dedicated cell and gene therapy leaders—supported by a multi-disciplinary team of scientific and operational specialists—can provide comprehensive and strategic insights for more efficient movement and reduction of risk across critical milestones of your entire therapeutic development journey. No matter where you are or where you intend to go, we’re here to provide the global testing infrastructure you need combined with the personalized experience you deserve. Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions.  

Learn more about Labcorp's comprehensive cell and gene therapy solutions here.


The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the Joint Force across combined Joint All-Domain Operations. JPEO- CBRND’s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. 

The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) facilitates the rapid response, advanced development, manufacturing and acquisition of medical solutions, such as vaccines, therapeutics, and diagnostics, to combat CBRN and emerging threats. 

To learn more about the JPEO-CBRND, visit:, or follow the JPEO-CBRND on social media @JPEOCBRND.

Disclaimer: The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government, and shall not be used for advertising or product endorsement purposes. The mention of companies by name is solely for the purpose of representing Command collaborations, and should not be implied as an endorsement.


Harvard and Resilience established a five-year R&D alliance in 2021, directed toward the development of complex medicines, including biologics, vaccines, nucleic acids and cell and gene therapies.

Defining a Future Together​

Interested in partnering with Resilience? We’d welcome the opportunity to discuss how we might be able to help you meet your goals while fundamentally changing the industry for the better.